Abstract
We are not aware of published cost-effectiveness studies addressing community transitional programs for HIV-infected jail detainees. To address this gap, data from 9 sites of EnhanceLink, a project that enrolled HIV-infected releasees from jails across the US, were examined. Figures on the number of clients served, cost of linkage services, number of linkages and 6-month sustained linkages to community HIV care, and number of clients achieving viral suppression were assessed for subjects released in the first quarter of 2010 (n = 543). The cost analysis included all costs that participating service agencies incurred. A cost-effectiveness analysis was conducted to estimate the new HIV cases averted by EnhanceLink and the cost per quality-adjusted life year saved by the program. The mean cost per linked client was $4,219; the mean cost per 6-month sustained linkage was $4,670; and the mean cost per client achieving viral suppression was $8,432. Compared to standard care, the cost per additional quality-adjusted life year saved was $72,285, suggesting that the EnhanceLink interventions were cost-effective from the societal perspective.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Spaulding AC, Seals RM, Page MJ, Brzozowski AK, Rhodes W, Hammett TM. HIV/AIDS among inmates of, and releasees from, US correctional facilities, 2006 declining share of epidemic but persistent public health opportunity. PLoS One. 2009;4(11):e7558. doi:10.1371/journal.pone.0007558.
Westergaard RP, Kirk GD, Richesson DR, Galai N, Mehta SH. Incarceration predicts virologic failure for HIV-infected injection drug users receiving antiretroviral therapy. Clin Infect Dis. 2011;53(7):725–31.
National HIV/AIDS strategy for the United States. 2010. http://www.whitehouse.gov/sites/default/files/uploads/NHAS.pdf. Accessed 3 Dec 2010.
Shrestha RK, Sansom SL, Richardson-Moore A, et al. Costs of voluntary rapid HIV testing and counseling in jails in 4 states advancing HIV prevention demonstration project 2003–2006. Sex Transm Dis. 2009;36(Suppl 2):S5–8.
Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr: JAIDS. 2005;39(4):446–53.
Holtgrave DR, Hall HI, Rhodes PH, Wolitski RJ. Updated annual HIV transmission rates in the United States, 1977–2006 (Letter to the editor). J Acquir Immune Defic Syndr. 2009;50:236–8.
Draine J, Ahuja D, Altice FL, et al. Strategies to enhance linkages between care for HIV/AIDS in jail and community settings. AIDS Care. 2011;23(3):366–77.
Pinkerton S. HIV Transmission rate modeling: a primer, review, and extension. AIDS Behav. 2012;16(4):791–6.
Centers for Disease Control and Prevention. HIV surveillance—United States, 1981–2008. MMWR. 2011;60:689–93.
Prejean J, Song R, Hernandez A, et al. Estimated HIV incidence in the United States, 2006–2009. PLoS One. 2011;6(8):e17502.
Gardner LI, Metsch LR, Anderson-Mahoney P, et al. Efficacy of a brief case management intervention to link recently diagnosed HIV-infected persons to care. AIDS. 2005;19(4):423–31.
Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L. The economic burden of HIV in the US in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. JAIDS. 2006;43(4):451–7.
Gebo KA, Fleishman JA, Conviser R, et al. Contemporary costs of HIV healthcare in the HAART era. AIDS. 2010;24(17):2705–15.
Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. Med Care. 2006;44(11):990–7.
Farnham PG, Sansom SL, Hutchinson AB. How much should we pay for a new HIV diagnosis? A mathematical model of HIV screening in US clinical settings. Méd Decis Mak. 2012;32(3):459–69.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–9.
Centers for disease control and prevention. HIV cost-effectiveness. 2012. http://www.cdc.gov/hiv/topics/preventionporgrams/ce/index.htm. Accessed 15 Jun 2012.
CDC'S new high-impact approach to HIV prevention funding for health departments advancing the national HIV/AIDS strategy. Fact sheet. 2011. http://www.cdc.gov/hiv/topics/funding/PS12-1201/resources/factsheet/pdf/foa-partner.pdf. Accessed 5 Sept 2011.
NIH, office of AIDS research. Translating research from bench to bedside to community. 2010. http://www.oar.nih.gov/strategicplan/fy2011/pdf/FY2011ByPassPlan_08_Plan.pdf in FY Trans-NIH Plan for HIV-related research, available at: http://www.oar.nih.gov/strategicplan/fy2011/index.asp. Accessed 6 Mar 2010.
Cohen SM, van Handel MM, Branson BM, et al. Vital Signs: HIV prevention through care and treatment—United States MMWR. 2011;60(47):1618–23.
Pinkerton SD. How many sexually-acquired HIV infections in the USA are due to acute phase HIV transmission? AIDS. 2007;21:1625–29.
Marks G, Crepaz N, Janssen RS. Estimating sexual transmission of HIV from persons aware and unaware that they infected with the virus in the USA. AIDS. Jun 26 2006;20(10):1447–50.
Acknowledgments
This study was supported, in part, by HRSA SPNS Cooperative Agreement U90HA07632; CFAR Grant P30 AI050409 from National Institute of Allergy and Infectious Disease (AS); and Center Grant P30-MH52776 from the National Institute of Mental Health (SP).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Spaulding, A.C., Pinkerton, S.D., Superak, H. et al. Cost Analysis of Enhancing Linkages to HIV Care Following Jail: A Cost-Effective Intervention. AIDS Behav 17 (Suppl 2), 220–226 (2013). https://doi.org/10.1007/s10461-012-0353-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-012-0353-4